Status:
UNKNOWN
Combined Haploidentical and Umbilical Cord Blood Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia
Lead Sponsor:
Institute of Hematology & Blood Diseases Hospital, China
Conditions:
Acute Leukemia
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
Allogeneic stem cell transplantation (Allo-HSCT) is the effective and even the only treatment option for acute leukemia. The haplo-hematopoietic stem cell transplantation(haplo-HSCT) and "GIAC" protoc...
Detailed Description
This prospective, randomized and controlled study is to investigate the efficacy and safety of Combined haploidentical and umbilical cord blood allogeneic stem cell transplantation. Investigators will...
Eligibility Criteria
Inclusion
- Ages 16-65 years inclusive.
- Diagnosed as acute leukemia, planning to receive haplo-HSCT
- Eastern Cooperative Oncology Group (ECOG) Performance status 0-2
- Presence of an available haploidentical donor
- Signing written informed consent and agreeing with taking designated umbilical cord blood
Exclusion
- Uncontrolled infections less than 4 weeks prior to enrollment
- Secondary malignancy
- Psychiatric illness that would limit compliance with study requirements
- Impairment of heart, hepatic or renal function to such an extent that the patient, in the opinion of the investigator, will be exposed to an excessive risk if entered into this clinical study
- Allergic to blood products
- Other causes which are not suitable for the trial in investigator's consideration
Key Trial Info
Start Date :
June 6 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2024
Estimated Enrollment :
116 Patients enrolled
Trial Details
Trial ID
NCT05335226
Start Date
June 6 2022
End Date
March 1 2024
Last Update
August 11 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, China, 300041